DK0779810T3 - Anvendelse af ketoconazol og beslægtede stoffer i medikamenter til behandling af type II-diabetes - Google Patents

Anvendelse af ketoconazol og beslægtede stoffer i medikamenter til behandling af type II-diabetes

Info

Publication number
DK0779810T3
DK0779810T3 DK94927881T DK94927881T DK0779810T3 DK 0779810 T3 DK0779810 T3 DK 0779810T3 DK 94927881 T DK94927881 T DK 94927881T DK 94927881 T DK94927881 T DK 94927881T DK 0779810 T3 DK0779810 T3 DK 0779810T3
Authority
DK
Denmark
Prior art keywords
ketoconazole
diabetes
drugs
type
treatment
Prior art date
Application number
DK94927881T
Other languages
Danish (da)
English (en)
Inventor
Per Marin
Original Assignee
Cortendo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortendo Ab filed Critical Cortendo Ab
Application granted granted Critical
Publication of DK0779810T3 publication Critical patent/DK0779810T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B1/00—Packaging fluent solid material, e.g. powders, granular or loose fibrous material, loose masses of small articles, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B1/04—Methods of, or means for, filling the material into the containers or receptacles
    • B65B1/08—Methods of, or means for, filling the material into the containers or receptacles by vibratory feeders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Mechanical Engineering (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK94927881T 1994-08-09 1994-08-09 Anvendelse af ketoconazol og beslægtede stoffer i medikamenter til behandling af type II-diabetes DK0779810T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SE1994/000729 WO1996004912A1 (fr) 1994-08-09 1994-08-09 Utilisation de cetoconazole et de substances apparentees dans des medicaments pour le traitement du diabete de type ii

Publications (1)

Publication Number Publication Date
DK0779810T3 true DK0779810T3 (da) 2003-10-20

Family

ID=20393155

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94927881T DK0779810T3 (da) 1994-08-09 1994-08-09 Anvendelse af ketoconazol og beslægtede stoffer i medikamenter til behandling af type II-diabetes

Country Status (14)

Country Link
US (2) US5849740A (fr)
EP (2) EP1360960A1 (fr)
JP (1) JP3825469B2 (fr)
KR (1) KR100422162B1 (fr)
AT (1) ATE244009T1 (fr)
CA (1) CA2196174C (fr)
CZ (1) CZ285290B6 (fr)
DE (1) DE69432905T2 (fr)
DK (1) DK0779810T3 (fr)
ES (1) ES2202326T3 (fr)
NO (1) NO314616B1 (fr)
PT (1) PT779810E (fr)
SI (1) SI0779810T1 (fr)
WO (1) WO1996004912A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE244009T1 (de) * 1994-08-09 2003-07-15 Metabolic Syndrome I Gbg Ab Verwendung von ketoconazol und verwandten substanzen in medikamenten für die behandlung des typ ii-diabetes
US6642236B1 (en) * 1998-12-14 2003-11-04 Cortendo Ab Methods for prophylactic treatment of cardiovascular disease with inhibitor of cortisol synthesis
SE9700642D0 (sv) 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet
GB0001449D0 (en) * 2000-01-21 2000-03-08 Cortendo Ab Compositions
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
GB0118300D0 (en) * 2001-07-26 2001-09-19 Cortendo Ab Formulations
US7081358B2 (en) * 2001-08-23 2006-07-25 New England Biolabs, Inc. Method for engineering strand-specific, sequence-specific, DNA-nicking enzymes
EA200400707A1 (ru) 2001-11-22 2004-10-28 Биовитрум Аб Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
EP1533619B1 (fr) 2003-11-20 2009-04-29 F. Hoffmann-Roche AG Marqueurs spécifiques du syndrome métabolique.
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
CN101141964B (zh) 2005-01-10 2013-06-05 科尔泰多投资公司 治疗糖尿病、代谢综合症和其它病症的组合物及方法
US20100280046A1 (en) * 2006-01-10 2010-11-04 Diobex, Inc. Methods and Compositions for Treating Prostate Cancer, Benign Prostatic Hypertrophy, Polycystic Ovary Syndrome and Other Conditions
JP2006206605A (ja) * 2006-03-29 2006-08-10 Metabolic Syndrome I Goeteborg Ab 代謝性症候群の治療薬
EP1886695A1 (fr) * 2006-06-27 2008-02-13 Speedel Experimenta AG Combinaisons pharmacéutiques avec inhibiteurs de l'aldosterone synthase et antagonistes du recepteur de glucocorticoides où inhibiteurs de la synthese de cortisol où antagonistes du facteur de libération de la corticotropine
RU2009116632A (ru) 2006-10-02 2010-11-10 Кортендо Инвест, Аб (Se) Энантиомер кетоконазола у людей
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432176A (en) * 1988-11-29 1995-07-11 The John Hopkins University Method of retarding the progression of chronic renal failure
US5175144A (en) * 1988-11-29 1992-12-29 The Johns Hopkins University Method of retarding the progression of chronic renal failure
ATE244009T1 (de) * 1994-08-09 2003-07-15 Metabolic Syndrome I Gbg Ab Verwendung von ketoconazol und verwandten substanzen in medikamenten für die behandlung des typ ii-diabetes
US5591736A (en) * 1995-07-03 1997-01-07 The Johns Hopkins University Method of retarding the progression of chronic renal failure

Also Published As

Publication number Publication date
PT779810E (pt) 2003-11-28
CA2196174C (fr) 2005-03-01
SI0779810T1 (en) 2003-12-31
NO970567L (no) 1997-02-07
ATE244009T1 (de) 2003-07-15
NO970567D0 (no) 1997-02-07
EP1360960A1 (fr) 2003-11-12
CZ36097A3 (en) 1997-06-11
WO1996004912A1 (fr) 1996-02-22
US5849740A (en) 1998-12-15
KR100422162B1 (ko) 2004-07-07
CZ285290B6 (cs) 1999-06-16
JPH10510241A (ja) 1998-10-06
AU695011B2 (en) 1998-08-06
EP0779810B1 (fr) 2003-07-02
DE69432905T2 (de) 2004-05-27
ES2202326T3 (es) 2004-04-01
US6166017A (en) 2000-12-26
NO314616B1 (no) 2003-04-22
JP3825469B2 (ja) 2006-09-27
EP0779810A1 (fr) 1997-06-25
CA2196174A1 (fr) 1996-02-22
DE69432905D1 (de) 2003-08-07
EP0779810B8 (fr) 2003-09-17
KR970704440A (ko) 1997-09-06
AU7711894A (en) 1996-03-07

Similar Documents

Publication Publication Date Title
NO970567D0 (no) Anvendelse av ketoconazol og relaterte substanser i medikamenter for behandling av type II diabetes
CY1112034T1 (el) Μονοδιασπαρμενα μειγματα και μεθοδοι για την θεραπευτικη αγωγη του διαβητη
IS5194A (is) Notkun þíasólídíndíonafleiða við meðferð á fjölblöðrueggjastokkaheilkennum og þungunarsykursýki
CY1106791T1 (el) Συνδυασμοι αναστολεα (-ων) απορροφησης στερολης με καρδιαγγειακο παραγοντα (-ες) για τη θεραπεια αγγειακων καταστασεων
CY1110894T1 (el) Μεθοδοι για θεραπεια ή προληψη αγγειακης φλεγμονης χρησιμοποιωντας αναστολεα (-εις) απορροφησης στερολης
KR970706002A (ko) 남성의 상대적 안드로겐 결핍증 치료를 위한 약제의 제조에 있어서 아로마타제 억제제의 용도(Use of Aromatase Inhibitors in the Preparation of a Drug for Treating a Relative Androgen Deficiency in Men)
EA200100289A1 (ru) Способ введения инсулинотропных пептидов
ATE367169T1 (de) Verwendung von exendins und deren agonisten zur behandlung von schwangerschaftsdiabetes
NO20006194L (no) Farmasöytisk sammensetning for behandling av funksjonell dyspepsi og/eller irriterbar innvollssyndrom og ny anvendelse av substanser deri
NO20041203L (no) Human glukagonlignende peptid-1 etterligner og deres anvendelse i behandling av diabetes og relaterte tilstander.
DE69527847D1 (de) Verwendung von anti-vegf-mitteln zur behandlung der endometriose
NO974824L (no) Arteriovenöse og venöse transplantasjonsbehandlinger, fremgangsmåter og blandinger
DK1143955T3 (da) En kombination af FBPase-inhibitorer og insulinsensibiliseringsmidler til behandling af diabetes
IS5756A (is) Notkun hreinljósvirks (+) -norkisapríðs við meðhöndlun á öndunarstöðvun, lotugræðgi og öðrum meinum
SE9700642D0 (sv) Medel och sätt för förebyggande och behandling av det metabola syndromet
DE60012517D1 (de) Methoden zur behandlung von diabetes
TNSN07372A1 (en) Method of treating or preventing type - 2 diabetes
EP1757302A8 (fr) Inducteur de l'expression de l'adiponectine et son utilisation
NO894008L (no) Trekonserveringsmiddel og fremgangsmaate for behandling avtre med samme.
WO2005053728A3 (fr) Protéines associées à l'adiposité et leur utilisation à des fins thérapeutiques et diagnostiques
ATE245029T1 (de) Verwendung von methoxymorpholino doxorubicin zur behandlung eines lebertumor
WO1999013894A3 (fr) Utilisation d'ifn-alpha et d'amantadine dans le traitement de l'hepatite c chronique
UA32255A (uk) Спосіб лікування цукрового діабету
Nanda et al. The Role of Single Dose Heparin in Prevention of Thrombus Formation in a New Experimental Thrombosis Model
Song Infection and the impact on cost effectiveness in wound care